Noraker is a leader in the development of bioactive medical devices towards bone regeneration. The company owns a unique know-how in the processing of composite implants made of 45S5 bioactive glass, a revolutionary biomaterial that triggers osteostimulation, a biological phenomenon which guarantees a fast and complete restoration of the patient’s bone capital.
This is a major advantage as compared to conventional implant, which often requires a 2nd surgical intervention to be removed because of side effects, leaving a critical sized gap to be treated with a bone graft.
To this day, Noraker has combined an absorbable polymer with 45S5 bioactive glass in one single bioactive composite fixation implant for the knee, named LockActiv.
The ambition of Noraker is go much farther and design implants to regenerate the full skeleton. This requires developing a “universal” bioactive composite formulation (= the main technical goal of the SMEI Phase 1 project).
Regarding the impact of the project:
- The ageing of the European population boosts market opportunities for regenerative medicine products and increases cost pressures on healthcare providers. It is not enough anymore for an implant to be bioresorbable in bone trauma. The demand for full bone regeneration products is now strongly expressed by surgeons, hospitals and specialized distributors. Therefore, NORAKER’s bone regeneration REBOOT toolbox is expected to raise major attention from the market.
- The REBOOT implants will stand ahead of the competition. There will be no equivalent offer and the biocomposite toolbox will challenge the products of the biggest players in the market .
- NORAKER will use a single multipotent bioactive composite formulation, shaped in different implant designs. This opens an opportunity to access the market faster: only one product will have to follow the entire validation process as requested by the new regulation on medical devices. The other biocomposite implant designs will benefit from the precedence on the market.
